ProCE Banner Activity

Practical Case Discussions: BTK inhibitor Therapy for MCL

Slideset Download
Download these slides from our ASH 2019 live satellite symposium on frontline of BTK inhibitors to review the most current clinical data on treating patients with MCL

Released: December 06, 2019

Expiration: December 04, 2020

No longer available for credit.

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly

Program Director Disclosure

Program Director

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Seattle Genetics, TG Therapeutics, and Verastem Oncology and funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno, Karyopharm Therapeutics, Kite Pharma, Merck, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Roche, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Unum, and Verastem Oncology.